"Ilus, Tuire" - Selaus tekijän mukaan TUNICRIS-julkaisut
Viitteet 1-8 / 8
-
Combining biological therapies in patients with inflammatory bowel disease: a Finnish multi-centre study
(2022)
articleBackground and aims: Therapy with two concomitant biologicals targeting different inflammatory pathways has emerged as a new therapy option for treatment refractory inflammatory bowel disease (IBD). Data on the efficacy ... -
Crohn’s disease: Risk of surgery among newly diagnosed patients
(2026)
articleBackground and objective: Medical treatment and treatment goals for Crohn’s disease (CD) have evolved over the past 20 years. The aim of the study was to assess the cumulative risk of surgery in newly diagnosed CD patients ... -
Long-term outcome of patients with acute ulcerative colitis after first course of intravenous corticosteroids
(2021)
article<p>Background and aims: Every fifth patient with ulcerative colitis (UC) experiences severe acute flare at some point in the course of the disease. Corticosteroids (Cs) remain the treatment of choice in acute flare. ... -
Long-term outcomes of patients with acute severe ulcerative colitis treated with cyclosporine rescue therapy
(17.11.2022)
article<p>BACKGROUND AND AIMS: The early outcomes of ulcerative colitis (UC) after rescue therapy with cyclosporine A (CyA) are well known. Published data on the safety of this treatment in perioperative use and data on the ... -
Measured levels of positive transglutaminase 2 antibodies are not associated with presentation or incidental endoscopic findings at celiac disease diagnosis
(2024)
articleObjectives: It has been suggested that celiac disease could be diagnosed non-invasively in adults with transglutaminase antibody (TGA) levels >10x upper limit of normal (ULN). It is, however, unclear if high values ... -
A nationwide real-world study on dynamic ustekinumab dosing and concomitant medication use among Crohn’s disease patients in Finland
(04 / 2021)
article<p>Background: Real-world evidence to support optimal ustekinumab dosing for refractory Crohn’s disease (CD) patients remains limited. Data from a retrospective nationwide chart review study was utilized to explore ... -
Real-life treatment persistence and treatment outcomes of Finnish patients with inflammatory bowel disease receiving vedolizumab as first-line biological treatment
(30.06.2024)
articlePurpose: To analyze treatment persistence and treatment outcomes of vedolizumab as first-line biological treatment in Crohn's disease (CD) and ulcerative colitis (UC) patients in a Finnish real-world setting. Methods: ... -
Risk of colectomy is decreasing among newly diagnosed Finnish ulcerative colitis patients
(01.06.2025)
articleBackground and Aims The risk of colectomy in patients with ulcerative colitis (UC) has decreased since the 20th century. Our aim was to determine the colectomy risk of newly diagnosed Finnish UC patients and compare the ...
